Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)
Effect of nintedanib on categorical changes in FVC in patients with progressive fibrosing ILDs: further analyses of the INBUILD trial
Maher TM et al.
Continued treatment with nintedanib in patients with progressive fibrosing autoimmune disease‑related interstitial lung diseases: data from INBUILD‑ON
Matteson EL et al.
Safety and tolerability of nintedanib in patients with autoimmune disease‑related interstitial lung diseases: pooled data from the SENSCIS and INBUILD trials
Smith V et al.
SC-ES-08021